Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2026
Continuous Glucose Monitoring for Postkidney Transplantation in Patient With Pre-existing Type 2 Diabetes.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bacha Dania Salih, Xiao Huijun, Paulus Kelly, Isaacs Diana, Malloy Kevin, Gossman Mona, Wee Alvin, Lansang M Cecilia
Аннотация
BACKGROUND: Kidney transplantation poses glycemic control challenges for type 2 diabetes mellitus due to immunosuppressive therapy and metabolic changes. In this pilot study, we aimed to assess glucometrics achieved with a continuous glucose monitor (CGM)-based insulin titration protocol during prednisone taper postkidney transplant.
METHODS: Kidney transplant recipients with pre-existing type 2 diabetes mellitus on insulin therapy were enrolled. CGM metrics were used to adjust insulin dose for 3 months. Data up to 6 months were included. CGM metrics, insulin and prednisone doses, kidney function, and clinical outcomes were analyzed.
RESULTS: Time in range increased from 44.2% to 60.8% at 3 months (P = .005) and 72.9% at 6 months (P < .001). TBR 54-69 mg/dL was 0.3% baseline, 0.4% at 3 months (P = .11) and 0.6% at 6 months (P = .036), whereas TBR <54 mg/dL was 0% at baseline with no significant increase at 3 and 6 months. Average glucose decreased from 194.7 mg/dL to 160.6 mg/dL at 3 months and 148.0 mg/dL at 6 months (P < .001). The estimated mean total insulin dose per kg body weight was 0.48 units/kg at baseline, 0.66 units/kg at 3 months, and 0.56 units/kg at 6 months.
CONCLUSION: These findings may assist with better insulin dosing for programs that have similar patient demographics and prednisone taper.
METHODS: Kidney transplant recipients with pre-existing type 2 diabetes mellitus on insulin therapy were enrolled. CGM metrics were used to adjust insulin dose for 3 months. Data up to 6 months were included. CGM metrics, insulin and prednisone doses, kidney function, and clinical outcomes were analyzed.
RESULTS: Time in range increased from 44.2% to 60.8% at 3 months (P = .005) and 72.9% at 6 months (P < .001). TBR 54-69 mg/dL was 0.3% baseline, 0.4% at 3 months (P = .11) and 0.6% at 6 months (P = .036), whereas TBR <54 mg/dL was 0% at baseline with no significant increase at 3 and 6 months. Average glucose decreased from 194.7 mg/dL to 160.6 mg/dL at 3 months and 148.0 mg/dL at 6 months (P < .001). The estimated mean total insulin dose per kg body weight was 0.48 units/kg at baseline, 0.66 units/kg at 3 months, and 0.56 units/kg at 6 months.
CONCLUSION: These findings may assist with better insulin dosing for programs that have similar patient demographics and prednisone taper.